<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473625</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01B</org_study_id>
    <nct_id>NCT04473625</nct_id>
  </id_info>
  <brief_title>Stool Collection Sub-Study of Exact Sciences Protocol 2018-01</brief_title>
  <official_title>Stool Collection Sub-Study of Exact Sciences Protocol 2018-01: &quot;Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exact Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exact Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this sub-study is to obtain de-identified, clinically characterized,&#xD;
      stool specimens from subjects with untreated solid tumors for research use in the development&#xD;
      and validation of a stool-based test for colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stool-based test for colorectal cancer</measure>
    <time_frame>Point in time (one day) stool collection within 30 days of enrollment</time_frame>
    <description>Research for the development and validation of a stool-based test for colorectal cancer</description>
  </primary_outcome>
  <number_of_groups>12</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Breast</arm_group_label>
    <description>Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung</arm_group_label>
    <description>Subjects with clinically confirmed lung cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal</arm_group_label>
    <description>Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate</arm_group_label>
    <description>Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bladder</arm_group_label>
    <description>Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uterine</arm_group_label>
    <description>Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney/Renal Pelvis</arm_group_label>
    <description>Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian</arm_group_label>
    <description>Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver</arm_group_label>
    <description>Subjects with clinically confirmed liver cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pancreas</arm_group_label>
    <description>Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stomach</arm_group_label>
    <description>Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esophageal</arm_group_label>
    <description>Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stool Sample Collection</intervention_name>
    <description>Subjects participating in the study will provide a stool sample within 30 days of enrollment.</description>
    <arm_group_label>Bladder</arm_group_label>
    <arm_group_label>Breast</arm_group_label>
    <arm_group_label>Colorectal</arm_group_label>
    <arm_group_label>Esophageal</arm_group_label>
    <arm_group_label>Kidney/Renal Pelvis</arm_group_label>
    <arm_group_label>Liver</arm_group_label>
    <arm_group_label>Lung</arm_group_label>
    <arm_group_label>Ovarian</arm_group_label>
    <arm_group_label>Pancreas</arm_group_label>
    <arm_group_label>Prostate</arm_group_label>
    <arm_group_label>Stomach</arm_group_label>
    <arm_group_label>Uterine</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool Collection&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be men and women, 18 years of age or older, who enroll in Exact Sciences&#xD;
        Protocol 2018-01. Approximately 450 subjects will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is currently enrolled in Exact Sciences Protocol 2018-01.&#xD;
&#xD;
          -  Subject is willing and able to provide a stool sample.&#xD;
&#xD;
          -  Subject understands the study procedures and is able to provide written informed&#xD;
             consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a condition the Investigator believes would interfere with his or her&#xD;
             ability to provide informed consent, comply with the sub-study protocol, or put the&#xD;
             person at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalie Hernandez</last_name>
    <phone>608-405-0389</phone>
    <email>nhernandez@exactsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarrett Schonbrun</last_name>
      <email>jschonbrun@acrcresearch.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Modiano-Revah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sellers</last_name>
      <phone>501-624-7700</phone>
      <email>lsellers@genesiscancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Webb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARTI Cancer Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Randall</last_name>
      <phone>501-906-3012</phone>
      <email>crandall@carti.com</email>
    </contact>
    <investigator>
      <last_name>Kamal Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang</last_name>
      <phone>415-925-5000</phone>
      <email>jchang@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Jennifer Lucas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Easter Ct Hematology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CSNF- Central Business Office</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Dacus</last_name>
      <email>Tiffany.Dacus@CSNF.us</email>
    </contact>
    <investigator>
      <last_name>Miten Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Institute - Oncology Research</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Eklund, M.S</last_name>
      <phone>952-993-5710</phone>
      <email>justin.eklund@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Lerner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Dominic's Gynecologic Oncology</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Humphreys</last_name>
      <phone>601-200-4479</phone>
      <email>jhumphreys@stdom.com</email>
    </contact>
    <investigator>
      <last_name>Donald Paul Seago</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameo Windham, BSN, RN</last_name>
      <phone>336-832-0825</phone>
      <email>phnacelle.windham@conhealth.com</email>
    </contact>
    <investigator>
      <last_name>Vinay K Gudena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Pinson</last_name>
      <email>wpinson@jacksonclinic.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Cancer Trials of Utah</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Waters</last_name>
      <email>admin@communitycancertrials.com</email>
    </contact>
    <investigator>
      <last_name>Carl Gray</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CAMC Clinical Trials Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Sutphin</last_name>
      <email>kristi.sutphin@camc.org</email>
    </contact>
    <investigator>
      <last_name>Steven Jubelirer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Cologuard</keyword>
  <keyword>Sample Collection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in publications of the study will be shared after deidentification. This may include text, tables, figures, and appendices. The study protocol and informed consent form (when applicable) will also be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be available from 2 years and ending 4 years after publication. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.</ipd_time_frame>
    <ipd_access_criteria>Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/EC approvals or waivers as applicable to conduct research. Data will be available between 2 and 4 years after publication through the Sponsor.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

